Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.25 USD | +0.96% | -2.60% | -34.21% |
May. 08 | Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024 | CI |
May. 08 | Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company appears highly valued given the size of its balance sheet.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-34.21% | 506M | C- | ||
+3.91% | 109B | B+ | ||
+10.87% | 105B | B+ | ||
+1.28% | 22.25B | B | ||
-13.14% | 22.09B | B+ | ||
-7.05% | 18.68B | A- | ||
-38.36% | 17.58B | A- | ||
-10.66% | 16.85B | B | ||
+3.75% | 13.76B | C+ | ||
+36.70% | 12.46B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ALEC Stock
- Ratings Alector, Inc.